Check-Cap

Check-Cap is a clinical-stage medical diagnostics company aiming to redefine colorectal cancer (CRC) screening through the introduction of C-Scan, a patient-friendly, preparation-free screening test that enables early intervention and cancer prevention by detecting polyps before they may develop into colorectal cancer. The company’s capsule-based screening technology is designed to significantly increase screening adherence worldwide, helping millions of people to stay healthy through preventive CRC screening. C-Scan uses an ultra-low dose X-ray capsule; an integrated positioning, control, and recording system; and proprietary software to generate a 3D map of the inner lining of the colon as the capsule travels naturally along the gastrointestinal tract. C-Scan is noninvasive and requires no sedation or bowel preparation, allowing patients to continue their daily routine without interruption. C-Scan is not intended to replace colonoscopies, and a positive C-Scan result should be followed by colonoscopy. In March 2021, the FDA approved Check-Cap’s investigational device exemption application, permitting it to begin a pivotal study of C-Scan in the United States.

Check-Cap has raised $134.22M in total funding across 15 rounds. The company is currently at the Public stage. Key investors include Undisclosed Investor(s), Intempo Ventures, Docor International Management.

Check-Cap was founded in 2005 by Yoav Kimchy (Founder & CTO).

Check-Cap operates in Health Tech & Life Sciences, Digital Healthcare, Digital Medical Diagnostics, Medical Devices, Diagnostics Devices, with core technologies in Simulation & Imaging, Platforms & Interfaces, Software, Artificial Intelligence, Deep Learning. Target customers: Healthcare & Life Sciences, Healthcare, Patients, Providers.

Check-Cap is based in Abba Hushi Boulevard 29, Isfiya, Israel, North District.